A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype-Reference-Cited by-同舟云学术

A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype

Published:2018-05-10 Issue:32 Volume:37 Page:4372-4384
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Kota Smitha,Hou Shurong,Guerrant William,Madoux Franck,Troutman Scott,Fernandez-Vega Virneliz,Alekseeva Nina,Madala Neeharika,Scampavia Louis,Kissil Joseph,Spicer Timothy P.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/s41388-018-0257-5.pdf

Reference40 articles.

1. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74.

2. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11–22.

3. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012;72:2457–67.

4. Gysin S, Salt M, Young A, McCormick F. Therapeutic strategies for targeting ras proteins. Genes Cancer. 2011;2:359–72.

5. Singh A, Settleman J. Oncogenic K-ras “addiction” and synthetic lethality. Cell Cycle. 2009;8:2676–7.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluating New Drugs against K-Ras4B/PDE6δ Using an in Vitro Approach;Technologies in Cell Culture - A Journey From Basics to Advanced Applications [Working Title];2023-10-31

2. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer;Nature Communications;2023-10-10

3. 3D culture of fibroblasts and neuronal cells on microfabricated free-floating carriers;Colloids and Surfaces B: Biointerfaces;2023-07

4. SIGNATURE-DRIVEN REPURPOSING OF MIDOSTAURIN FOR COMBINATION WITH MEK1/2 AND KRASG12C INHIBITORS IN LUNG CANCER;2023-06-26

5. A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming;Oncogene;2022-10-15